Plasma Pentraxin-3 Combined with Plaque Characteristics Predict Cardiovascular Risk in ST-Segment Elevated Myocardial Infarction: An Optical Coherence Tomography Study

References

• Goodman AR, Cardozo T, Abagyan R, Altmeyer A, Wisniewski HG, Vilcek J. Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev. 1996;7(2):191–202. doi:10.1016/1359-6101(96)00019-6
   PubMedGoogle Scholar
• Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102(6):636–641. doi:10.1161/01.CIR.102.6.636
   PubMed Web of Science ®Google Scholar
• Helseth R, Solheim S, Opstad T, Hoffmann P, Arnesen H, Seljeflot I. The time profile of pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention. Mediators Inflamm. 2014;2014:608414. doi:10.1155/2014/608414
   PubMed Web of Science ®Google Scholar
• Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22(5):e10–4. doi:10.1161/01.ATV.0000015595.95497.2F
   PubMed Web of Science ®Google Scholar
• Kimura S, Sugiyama T, Hishikari K, et al. Relationship of systemic pentraxin-3 values with coronary plaque components on optical coherence tomography and post-percutaneous coronary intervention outcomes in patients with stable angina pectoris. Atherosclerosis. 2020;292:127–135. doi:10.1016/j.atherosclerosis.2019.11.022
   PubMed Web of Science ®Google Scholar
• Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310(18):1137–1140. doi:10.1056/NEJM198405033101801
   PubMed Web of Science ®Google Scholar
• Niccoli G, Montone RA, Di Vito L, et al. Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. Eur Heart J. 2015;36(22):1377–1384. doi:10.1093/eurheartj/ehv029
   PubMed Web of Science ®Google Scholar
• Koga S, Ikeda S, Yoshida T, et al. Elevated levels of systemic pentraxin 3 are associated with thin-cap fibroatheroma in coronary culprit lesions: assessment by optical coherence tomography and intravascular ultrasound. JACC Cardiovasc Interv. 2013;6(9):945–954. doi:10.1016/j.jcin.2013.04.024
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–177.
   PubMed Web of Science ®Google Scholar
• Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the international working group for intravascular optical coherence tomography standardization and validation. J Am Coll Cardiol. 2012;59(12):1058–1072. doi:10.1016/j.jacc.2011.09.079
   PubMed Web of Science ®Google Scholar
• Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J. 2011;32(17):2125–2134. doi:10.1093/eurheartj/ehr213
   PubMed Web of Science ®Google Scholar
• Farooq V, van Klaveren D, Steyerberg EW, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013;381(9867):639–650. doi:10.1016/S0140-6736(13)60108-7
   PubMed Web of Science ®Google Scholar
• Haibo L, Xiaofang G, Chunming W, et al. Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation. Mediators Inflamm. 2014;2014:963096. doi:10.1155/2014/963096
   PubMed Web of Science ®Google Scholar
• Gustin C, Delaive E, Dieu M, Calay D, Raes M. Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure. Arterioscler Thromb Vasc Biol. 2008;28(3):491–497. doi:10.1161/ATVBAHA.107.158642
   PubMed Web of Science ®Google Scholar
• Carrizzo A, Lenzi P, Procaccini C, et al. Pentraxin 3 induces vascular endothelial dysfunction through a p-selectin/matrix metalloproteinase-1 pathway. Circulation. 2015;131(17):1495–1505; discussion 1505. doi:10.1161/CIRCULATIONAHA.114.014822
   PubMed Web of Science ®Google Scholar
• Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009;29(4):594–599. doi:10.1161/ATVBAHA.108.178947
   PubMed Web of Science ®Google Scholar
• Matsui S, Ishii J, Kitagawa F, et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 2010;210(1):220–225. doi:10.1016/j.atherosclerosis.2009.10.033
   PubMed Web of Science ®Google Scholar
• Kimura S, Inagaki H, Haraguchi G, et al. Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction. Circ J. 2014;78(1):159–169. doi:10.1253/circj.CJ-13-0329
   PubMed Web of Science ®Google Scholar
• Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326(4):242–250. doi:10.1056/NEJM199201233260406
   PubMed Web of Science ®Google Scholar
• Narula J, Nakano M, Virmani R, et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol. 2013;61(10):1041–1051. doi:10.1016/j.jacc.2012.10.054
   PubMed Web of Science ®Google Scholar
• Kim HO, Kim CJ, Kurihara O, et al. Angiographic features of patients with coronary plaque erosion. Int J Cardiol. 2019;288:12–16. doi:10.1016/j.ijcard.2019.03.039
   PubMed Web of Science ®Google Scholar
• Jia H, Abtahian F, Aguirre AD, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol. 2013;62(19):1748–1758. doi:10.1016/j.jacc.2013.05.071
   PubMed Web of Science ®Google Scholar
• Hu S, Zhu Y, Zhang Y, et al. Management and outcome of patients with acute coronary syndrome caused by plaque rupture versus plaque erosion: an Intravascular Optical Coherence Tomography Study. J Am Heart Assoc. 2017;6(3):e004730. doi:10.1161/JAHA.116.004730
   PubMed Web of Science ®Google Scholar
• Hayıroğlu M, Keskin M, Uzun AO, et al. Predictive value of SYNTAX score II for clinical outcomes in cardiogenic shock underwent primary percutaneous coronary intervention; a pilot study. Int J Cardiovasc Imaging. 2018;34(3):329–336. doi:10.1007/s10554-017-1241-9
   PubMed Web of Science ®Google Scholar